Multiple Tumor Types

« Previous 12345 Next »
Viewing Page 1 of 7 | Showing Results 1 - 10 of 61

Implementing a Virtual Tobacco Treatment in Community Oncology Practices: Smoke Free Support Study 2.0.

This phase II trial studies how well smoking cessation treatment plans work in tobacco-dependent cancer patients when delivered virtually as part...

Alison Conlin, M.D.

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Montana, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.

An Open-Label, Non-Randomized, Multicenter Study to Determine the Pharmacokinetics and Safety of Niraparib Following A Single Oral Dose in Patients with Advanced Solid Tumors and Either Normal Hepatic Function or Moderate Hepatic Impairment

Evaluate pharmacokinetics of the study drug. Evaluate the safety of the study drug, niraparib, in cancer patients with moderate hepatic impairment.

Diana Hanna, M.D.
  • Hoag Research
  • xSJH Southern California

A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination with Atezolizumab in HLA-A*02+ Patients with HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

This is a Phase 1 open-label, multicenter study of the safety and tolerability, immunogenic effects, antitumor activity, and pharmacodynamics of...

Matthew Taylor, M.D.
  • Providence Cancer Institute Franz Clinic

Genetic drivers of metastases in rare cancers

The objective of this study is to analyze the molecular (DNA, RNA, protein) changes in tumor tissue or blood from people with rare tumors. These...

Michael Demeure, M.D.
  • Hoag Research
  • xSJH Southern California

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination With NKTR-214 and in Combination With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies

Patients will receive intratumoral (IT) NKTR-262 in 3-week treatment cycles. During the Phase 1 dose escalation portion of the trial, NKTR-262 will...

Brendan Curti, M.D.
  • Providence Cancer Institute Franz Clinic

JWC JWCI-18-0401 - John Wayne Cancer Institute Biospecimen and Research Data Repository

The purpose of this study is to collect clinical data and biological specimens (e.g., blood, tumor,cerebrospinal fluid, urine sample, etc.) from...

Jennifer Linehan, M.D.
  • John Wayne Cancer Institute (JWCI)
  • Providence St. Johns Health Center (PSJHC)

0S-15-5 A Pilot Multi-Arm Study of sEphB4-HSA In Combination with Different Chemotherapy Regimens in Patients with Specific Advanced or Metastatic Solid Tumors

This pilot phase Ib trial studies the side effects and best dose of recombinant EphB4-HSA fusion protein when given together with standard...

Diana Hanna, M.D.
  • Hoag Research
  • xSJH Southern California

A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS

Avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors,...

Diana Hanna, M.D.
  • Hoag Research
  • xSJH Southern California

ZWI-ZW25-101 (anti-Phase 1 trial of ZW25 in patients with locally advanced (unresectable) and/or metastatic HER2-expressing cancers

Phase 1 trial of ZW25 in patients with locally advanced (unresectable) and/or metastatic HER2-expressing cancers

Diana Hanna, M.D.
  • Hoag Research
  • xSJH Southern California

A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors

The purpose of this study is to assess the safety and tolerability, characterize the dose-limiting toxicities, and identify the maximum tolerated...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic
« Previous 12345 Next »
Viewing Page 1 of 7 | Showing Results 1 - 10 of 61